Suppr超能文献

高剂量白细胞介素-2和淋巴因子激活的杀伤细胞过继免疫疗法导致的严重维生素C缺乏症。

Severe hypovitaminosis C occurring as the result of adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells.

作者信息

Marcus S L, Dutcher J P, Paietta E, Ciobanu N, Strauman J, Wiernik P H, Hutner S H, Frank O, Baker H

出版信息

Cancer Res. 1987 Aug 1;47(15):4208-12.

PMID:3496958
Abstract

Adoptive immunotherapy of human cancer was investigated in our institution as part of a National Cancer Institute extramural group study. This treatment, for patients with metastatic malignant melanoma, hypernephroma, and colon carcinoma, consisted of three phases: (a) 5 days of i.v. high-dose (10(5) units/kg every 8 h) interleukin 2, (b) 6 1/2 days of rest plus leukapheresis; and (c) 4 days of high-dose interleukin 2 plus three infusions of autologous lymphokine-activated killer cells. Toxicities included fever, chills, tachycardia, hypotension, vomiting, diarrhea, and fluid retention. Ascorbic acid is known to be important to cell-mediated immunity, and it has been reported to be depleted during physiologically stressful events. Therefore, we determined plasma ascorbic acid levels in patients (n = 11) before adoptive immunotherapy and before and after Phases 1, 2, and 3 of treatment. Patients entering the trial were not malnourished. Mean plasma ascorbic acid levels were normal (0.64 +/- 0.25 mg/dl) before therapy. Mean levels dropped by 80% after the first phase of treatment with high-dose interleukin 2 alone (0.13 +/- 0.08 mg/dl). Mean plasma ascorbic acid levels remained severely depleted (0.08 to 0.13 mg/dl) throughout the remainder of the treatment, becoming undetectable (less than 0.05 mg/dl) in eight of 11 patients during this time. Values obtained from 24-h urine collections on two of two patients indicated that ascorbate was not excreted in the urine. Plasma ascorbic acid normalized in three of three patients tested 1 mo after the completion of treatment. Unlike the results for ascorbic acid, blood pantothenate and plasma vitamin E remained within normal limits in all 11 patients throughout the phases of therapy. Responders (n = 3) differed from nonresponders (n = 8) in that plasma ascorbate levels in the former recovered to at least 0.1 mg/dl (frank clinical scurvy) during Phases 2 and 3, whereas levels in the latter fell below this level.

摘要

作为美国国立癌症研究所一项院外小组研究的一部分,我们机构对人类癌症的过继性免疫疗法进行了研究。这种针对转移性恶性黑色素瘤、肾癌和结肠癌患者的治疗包括三个阶段:(a)静脉注射高剂量(每8小时10⁵单位/千克)白细胞介素2,持续5天;(b)休息6.5天并进行白细胞分离术;以及(c)高剂量白细胞介素2治疗4天,外加三次自体淋巴因子激活的杀伤细胞输注。毒性反应包括发热、寒战、心动过速、低血压、呕吐、腹泻和液体潴留。已知抗坏血酸对细胞介导的免疫很重要,并且据报道在生理应激事件期间会被消耗。因此,我们测定了11例患者在过继性免疫疗法前以及治疗第1、2和3阶段前及后的血浆抗坏血酸水平。进入试验的患者没有营养不良。治疗前血浆抗坏血酸平均水平正常(0.64±0.25毫克/分升)。仅用高剂量白细胞介素2进行第一阶段治疗后,平均水平下降了80%(0.13±0.08毫克/分升)。在治疗的其余时间里,血浆抗坏血酸平均水平仍严重缺乏(0.08至0.13毫克/分升),在此期间11例患者中有8例变得无法检测到(低于0.05毫克/分升)。对两名患者中的两名进行的24小时尿液收集结果表明,尿液中没有排出抗坏血酸盐。治疗完成1个月后,对三名接受测试的患者中的三名进行检测,其血浆抗坏血酸水平恢复正常。与抗坏血酸的结果不同,在治疗的各个阶段,所有11例患者的血液泛酸和血浆维生素E水平均保持在正常范围内。有反应者(3例)与无反应者(8例)的不同之处在于,前者的血浆抗坏血酸水平在第2和第3阶段恢复到至少0.1毫克/分升(明显的临床坏血病),而后者的水平则降至该水平以下。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验